Nick Haining, Arsenal Bio
Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO
Merck’s immuno-oncology superstar Nicholas Haining has been appointed CSO at ArsenalBio, which is working on an approach to programmable cell therapies.
The addition of a high-profile appointment like Haining, who co-founded the company but has been serving as VP of discovery oncology and immunology at Merck Research Laboratories and also did work on pediatric hematology/oncology at the famed Dana-Farber Cancer Institute, comes as ArsenalBio may set its sights on an IPO in the near future.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters